Benzinga | Apr 12, 2021 10:19AM EDT

Cardiff Oncology's Onvansertib Shows Durable Response, Progression-Free Survival In Colorectal Cancer Patients

* Cardiff Oncology Inc (NASDAQ: CRDF) has announced data from its ongoing Phase 1b/2 trial evaluating onvansertib combined with standard-of-care therapy in second-line KRAS-mutated metastatic colorectal cancer (mCRC).

* Patients enrolled in the trial receive onvansertib combined with standard-of-care Folfiri Chemo and Roche Holdings AG's (OTC:RHHBY) Avastin (bevacizumab).

* The overall response rate (ORR) in the trial is 39% to date, and onvansertib combined with Folfiri/bevacizumab has been well tolerated with no significant or unexpected toxicities attributed to onvansertib.

* The median progression-free survival of evaluable patients is 9.4 months.

* Clinical responses were observed across different KRAS mutations, including the three most common in colorectal cancer (G12D, G12V, G13D).

* The greatest decreases in plasma KRAS mutant allelic frequency (MAF) after one treatment cycle were observed in patients achieving a PR.

* All seven patients with a PR had a more than 75% decrease in KRAS MAF after one treatment cycle.

* The updated Phase 1b/2 mCRC trial data will be presented during a key opinion leader webinar to be held today at 11:00 a.m. ET.

* Price Action: CRDF shares are up 0.9% at $9.36 on the last check Monday.